957
Views
25
CrossRef citations to date
0
Altmetric
Research Article

Aryl acylamidase activity of human serum albumin with o-nitrotrifluoroacetanilide as the substrate

, , , &
Pages 463-469 | Received 24 Jan 2007, Accepted 18 Feb 2007, Published online: 04 Oct 2008
 

Abstract

Albumin is generally regarded as an inert protein with no enzyme activity. However, albumin has esterase activity as well as aryl acylamidase activity. A new acetanilide substrate, o-nitrotrifluoroacetanilide (o-NTFNAC), which is more reactive than the classical o-nitroacetanilide, made it possible to determine the catalytic parameters for hydrolysis by fatty-acid free human serum albumin. Owing to the low enzymatic activity of albumin, kinetic studies were performed at high albumin concentration (0.075 mM). The albumin behavior with this substrate was Michaelis-Menten like. Kinetic analysis was performed according to the formalism used for catalysis at high enzyme concentration. This approach provided values for the turnover and dissociation constant of the albumin-substrate complex: kcat = 0.13 ± 0.02 min − 1 and Ks = 0.67 ± 0.04 mM. MALDI-TOF experiments showed that unlike the ester substrate p-nitrophenyl acetate, o-NTFNAC does not form a stable adduct (acetylated enzyme). Kinetic analysis and MALDI-TOF experiments demonstrated that hydrolysis of o-NTFNAC by albumin is fully rate-limited by the acylation step (kcat = k2). Though the aryl acylamidase activity of albumin is low (kcat/Ks = 195 M− 1min− 1), because of its high concentration in human plasma (0.6–1 mM), albumin may participate in hydrolysis of aryl acylamides through second-order kinetics. This suggests that albumin may have a role in the metabolism of endogenous and exogenous aromatic amides, including drugs and xenobiotics.

Acknowledgements

This work was supported by Edgewood Biological Chemical Center, contract W911S-04-C-0019 (to OL), and DGA 03co010-05/PEA 01 08 7 and EMA/LR 06 to PM. Mass spectra were obtained with support from the Protein Structure Core Facility at the University of Nebraska Medical Center.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.